How to Cite
Abstract
The assessment of aggressiveness and risk of death in papillary thyroid cancer in children is currently based on clinical criteria. To ensure a more accurate risk stratification, new criteria and various molecular genetic markers are constantly being sought. The article studied the dependence of the clinical and pathological manifestations of papillary thyroid cancer in children on the level of expression of various microRNAs and the presence of the BRAF mutation. It was found that the BRAF mutation was present in 20.4% of cases, while the dependence of the clinical behavior of cancer on the BRAF mutation was not established. Of the 14 microRNAs studied, statistical differences were obtained for oncogenic miR-146b, -221, -31, and oncosuppressive miR-144, which correlated with signs such as extrathyroid tumor growth, multi-focus, and metastasis to the neck lymph nodes.
References
Diesen DL, Skinner MA. Pediatric thyroid cancer: Seminars in pediatric surgery // Elsevier. 2012:44-50.
Hogan AR, Zhuge Y, Perez EA et al. Pediatric thyroid carcinoma: Incidence and outcomes in 1753 patients // J Surg Res. 2009;156:167-72.
Parisi MT, Eslamy H, Mankoff D. Management of Differentiated Thyroid Cancer in Children: Focus on the American Thyroid Association Pediatric Guidelines // Semin Nucl Med. 2016;46(2):147–64.
Chan CM, Young J, Prager J et al. Pediatric Thyroid Cancer // Adv Pediatr. 2017;64(1):171–90.
Jarzab B, Handkiewicz-Junak D. Differentiated thyroid cancer in children and adults: same or distinct disease? // Hormones (Athens). 2007;6(3):200–9.
Клинические рекомендации. Рак щитовидной железы. Год утверждения 2020. Возрастная категория: Дети. ID: КР74/1 https: // doi: cr.rosminzdrav.ru/recomend/74
Hay ID, Gonzalez-Losada T, Reinalda MS et al. Long-term outcome in 215 children and adolescents with papillary thyroid cancer treated during 1940 through 2008 // World J. Surg. 2010;34:1192–1202.
Rubino C, de Vathaire F, Dottorini ME, et al. Second primary malignancies in thyroid cancer patients // Br J Cancer. 2003;89:1638–1644.
Brown AP, Chen J, Hitchcock YJ, et al. The risk of second primary malignancies up to three decades after the treatment of differentiated thyroid cancer // J Clin Endocrinol Metab. 2008;93:504–515.
Francis GL, Waguespack SG, Bauer AJ et al: Management guidelines for children with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association guidelines task force on pediatric thyroid cancer // Thyroid. 2015;25:716-759.
Tracy ET, Roman SA. Current management of pediatric thyroid disease and differentiated thyroidcancer // Current opinion in oncology. 2016;28:37-42.
Лукьянов С.А., Сергийко С.В., Титов С.Е. и др. Влияние мутации BRAF на клинико-патологические проявления папиллярного рака щитовидной железы // Таврический Медико-биологический вестник. 2020;23(2):85-92.
Yan C, Huang M, Li X, Wang T, Ling R. Relationship between BRAF V600E and clinical features in papillary thyroid carcinoma // Endocr Connect. 2019;8(7):988–996. https: // doi: 10.1530/EC-19-0246
Ma H, Wang R, Fang J et al. A meta-analysis evaluating the relationship between B-type Raf kinase mutation and cervical lymphatic metastasis in papillary thyroid cancer // Medicine (Baltimore). 2020;99(5):e18917. https: // doi: 10.1097/MD.0000000000018917
Mansoori B, Mohammadi A, Shirjang S, Baradaran B. Micro-RNAs: The new potential biomarkers in cancer diagnosis, prognosis and cancer therapy // Cell Mol Biol (Noisy-legrand). 2015;61:1–10.
Лукьянов С.А., Сергийко С.В., Титов С.Е. и др. Стратификация риска рецидива папиллярного рака щитовидной железы на основании результатов молекулярно-генетических исследований // Опухоли головы и шеи 2020;10(1):93–100.
Acibucu F, Dökmetaś HS, Tutar Y et al. Correlations between the expression levels of micro-RNA146b, 221, 222 and p27Kip1 protein mRNA and the clinicopathologic parameters in papillary thyroid cancers // Experimental and Clinical Endocrinology & Diabetes. 2014;122:137–143. https: // doi: 10.1055/s-0034-1367025.
Galuppini F, Vianello F, Censi S et al. Differentiated Thyroid Carcinoma in Pediatric Age: Genetic and Clinical Scenario // Front. Endocrinol. 2019;10:552. https: // doi: 10.3389/fendo.2019.00552
He H et al. The role of microRNA genes in papillary thyroid carcinoma // Proc Natl Acad Sci. 2005;102(52):19075-19,080. https: // doi: 10.1073/pnas.0509603102
Pallante P, Visone R, Ferracin M et al. MicroRNA deregulation in human thyroid papillary carcinomas // Endocr Rel at Cancer. 2006;13:497–508. https: // doi: 10.1677/erc.1.01209
Franco AT, Labourier E, Ablordeppey KK et al. miRNA expression can classify pediatric thyroid lesions and increases the diagnostic yield of mutation testing // Pediatr Blood Cancer. 2020 Jun;67(6):e28276. https: // doi: 10.1002/pbc.28276. Epub 2020 Mar 20. PMID: 32196952
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
© АННМО «Вопросы онкологии», Copyright (c) 2021